The present study examines the diagnostic challenges of identifying ante-mortem illicit
substance use in human postmortem cases.
Substance use, assessed by clinical case history reviews, structured next-of-kin interviews, by general toxicology of blood, urine and/or brain, and by scalp hair testing, identified 33
cocaine, 29 cannabis, 10
phencyclidine and nine
opioid cases. Case history identified 42%
cocaine, 76% cannabis, 10%
phencyclidine and 33%
opioid cases. Next-of-kin interviews identified almost twice as many
cocaine and cannabis cases as Medical Examiner (ME) case histories, and were crucial in establishing a detailed lifetime
substance use history. Toxicology identified 91%
cocaine, 68% cannabis, 80%
phencyclidine and 100%
opioid cases, with hair testing increasing detection for all drug classes. A
cocaine or cannabis use history was corroborated by general toxicology with 50% and 32% sensitivity, respectively, and with 82% and 64% sensitivity by hair testing. Hair testing corroborated a positive general toxicology for
cocaine and cannabis with 91% and 100% sensitivity, respectively. Case history corroborated hair toxicology with 38% sensitivity for
cocaine and 79% sensitivity for cannabis, suggesting that both case history and general toxicology underestimated
cocaine use. Identifying ante-mortem
substance use in human postmortem cases are key considerations in case diagnosis and for characterization of disorder-specific changes in neurobiology. The sensitivity and specificity of
substance use assessments increased when ME case history was supplemented with structured next-of-kin interviews to establish a detailed lifetime
substance use history, while comprehensive toxicology, and hair testing in particular, increased detection of recent illicit
substance use.